Ardelyx Valuation
Is ARDX * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ARDX * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ARDX * (MX$113.8) is trading below our estimate of fair value (MX$696.54)
Significantly Below Fair Value: ARDX * is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ARDX *?
Other financial metrics that can be useful for relative valuation.
What is ARDX *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$1.86b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 11.2x |
Enterprise Value/EBITDA | -29.4x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does ARDX *'s PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 11.5x | ||
BEAM Beam Therapeutics | 5.4x | -31.4% | US$2.0b |
RYTM Rhythm Pharmaceuticals | 25.8x | 44.7% | US$2.4b |
688520 Sinocelltech Group | 9.4x | 26.7% | CN¥20.7b |
MIRM Mirum Pharmaceuticals | 5.3x | 24.4% | US$1.2b |
ARDX * Ardelyx | 11.7x | 32.8% | Mex$1.9b |
Price-To-Sales vs Peers: ARDX * is expensive based on its Price-To-Sales Ratio (11.7x) compared to the peer average (11.5x).
Price to Earnings Ratio vs Industry
How does ARDX *'s PE Ratio compare vs other companies in the Global Biotechs Industry?
Price-To-Sales vs Industry: ARDX * is expensive based on its Price-To-Sales Ratio (11.7x) compared to the Global Biotechs industry average (10.3x).
Price to Sales Ratio vs Fair Ratio
What is ARDX *'s PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 11.7x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate ARDX *'s Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.